ArriVent BioPharma (AVBP) Stock: Buy, Sell, or Hold?
AVBP - ArriVent BioPharma, Inc. Common Stock
$29.00
0.30 (1.05%)
▲
5d:
-6.54%
30d:
-7.82%
90d:
-3.97%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $30.95 · last confirmed Sep 11, 2026
Strength: 6.9/10
Get Alerted When AVBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AVBP shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AVBP shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AVBP is currently trading at $29.00, which is considered oversold relative to its 30-day fair value range of $29.32 to $31.12.
Technical Outlook: Technically, AVBP is showing sideways momentum. The price is currently testing key support at $28.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AVBP scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $44.70 (+54.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AVBP is showing sideways momentum. The price is currently testing key support at $28.15. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AVBP scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $44.70 (+54.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$29.32 -
$31.12
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 54.1% below Wall St target ($44.70)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$29.32 -
$31.12
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$28.15
Resistance Level
$31.45
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.39
Wall Street Target
$44.70
(+54.1%)
Share & Embed Analysis
Last updated: September 12, 2026 7:06 PM ET
Data refreshes hourly during market hours. Next update: 8:06 PM
Data refreshes hourly during market hours. Next update: 8:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
